Khiron Life Sciences Corp (CVE:KHRN) Participation in National Cannabis Roundtable

By |

Watch

Midas Letter

The Digital Businesss Channel for Cannabis, Crypto and Technology Stocks.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Khiron Life Sciences Corp (CVE:KHRN) (OTCMKTS:KHRNF) (FRA:4KH) Chief Compliance Officer and Former DEA Agent, Matt Murphy joins James via Skype to discusses compliance and security programs on the cultivation site and team in Latin America, along with participation in the National Cannabis Roundtable (“NCR”). As part of its leadership role in LatAm, Khiron is at the forefront of implementing rigorous, DEA-level security protocols at its cultivation site in Bogota, Colombia. With Matt’s experience, Khiron can ensure consistent regulatory standards across all operations and all jurisdictions.  Earlier this year Khiron joined the newly formed NCR, which focuses on advocating for a rational legal framework for cannabis reform in the US. Khiron will work alongside the NCR’s Honorary Chairman, John Boehner, former Speaker of the House.

 

**IMPORTANT! BY VIEWING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**

Notice for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. Such forward-looking information includes that Khiron Life Sciences Corp will be a big, successful company in the cannabis sector; that cannabis use and sales will grow and KHIRON’s sales along with it; KHIRON’s intended acquisition of various foreign companies and expansion into the European and South and North American markets; that cosmeceuticals is and will continue to be a fast growing and profitable sector of the cannabis industry; and that it will be able to carry out its business plans.

 

Readers are cautioned to not place undue reliance on forward-looking information. Forward looking information is subject to a number of risks and uncertainties that may cause actual results or events to differ materially from those contemplated in the forward-looking information, and even if such actual results or events are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on KHIRON. Such risks and uncertainties include, among other things: that a regulatory approval that may be required for the intended acquisitions and subsequent sales are not obtained or are obtained subject to conditions that are not anticipated; growing competition for intended acquisitions in the cannabis industry; potential future competition in the markets KHIRON operates for sales; competitors may quickly enter the industry; general economic conditions in the US, Canada and globally; the inability to secure financing necessary to carry out its business plans; competition for, among other things, capital and skilled personnel; the possibility that government policies or laws may not permit legal cannabis sales or growth or that favorable laws in place may change; KHIRON not adequately protecting its intellectual property; interruption or failure of information technology systems; the cannabis market may not grow as expected; KHIRON’s technology may not achieve the expected results and its accomplishments may be limited; even if it is granted patents, it may not have success at licensing its technologies or sell its products at the rate expected; planned acquisitions and partnerships may not materialize because of inability to agree on terms with prospective partners or targets; KHIRON’s business plan also carries risk, including its ability to comply with all applicable governmental regulations in a highly regulated business; incubator risk investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal under US federal and foreign laws; and other regulatory risks relating to KHIRON’s business, financings and strategic acquisitions, including securities laws, trade rules, and foreign country regulation that is not the same as Canadian or US regulations.

 

DISCLAIMERS

PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. James West, Global Financial Network Ltd. and Midas Letter Media Corp. and their owners, managers, employees, and assigns (collectively “the Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by KHIRON $100,000 per month for one year as of May 15, 2019 for a newsletter campaign and certain banner ads, of which a portion is spent to produce multi-media content and a portion to the advertising budget targeting investor. In addition, the Company owns 150,000 Restricted Share Units (RSU’s) of KHIRON, and will benefit from its price appreciation. This compensation and our rights ownership in KHIRON is a major conflict with our ability to be unbiased, more specifically:

This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. We have been compensated by KHIRON to conduct investor awareness advertising and marketing for KHIRON. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the profiled company. The profiled company or its affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our newsletters experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.

We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public and non-public sources but is not researched or verified in any way whatsoever to ensure the information is correct.

SHARE OWNERSHIP. The Company, which includes the owner and publisher of the Midas Letter owns Restricted Share Units of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The Company will not notify the market when it decides to buy or sell shares of this profiled company in the market. The Company may be buying and selling additional shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

NOT AN INVESTMENT ADVISOR. The Company and its affiliates are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.

RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.

Transcript

James West: I’m joined now by Matt Murphy, Chief Compliance Officer of Khiron Life Sciences, trading on the TSX Venture under the symbol KHRN. Matt, welcome back.

Matt Murphy: Thanks James. It’s a pleasure to be with you again, I very much appreciate it.

James West: You bet. Matt, there’s a lot of uncertainty in minds of investors, arguably, about the ability of security to protect the interests of cannabis companies in not just Latin America but the entire world. And in your position as former DEA head of compliance and diversion, you’ve got some very specialized knowledge in that regard, and in fact, you’ve joined a roundtable consisting of some members and former DEA guys. Tell me about what you’re doing to mitigate the risk of security as it pertains to cultivation sites and everything in Latin America, as well as this roundtable.

Matt Murphy: Sure. So in regards to the security and compliance that Khiron is undertaking as we evolve and expand our operations globally, I have brought on several former high-level DEA investigators, managers that worked with me or that I knew from my time with DEA. These former high-level DEA management personnel have significant amount of experience working in countries where Khiron will be operating soon, or is operating now. For example, Larry Holifield is a former country attache for Mexico, which means he was the highest ranking DEA agent assigned to Mexico. He lived in Mexico for approximately four years. He was also assigned to Guatemala and has experience in Uruguay, all places that we expect to be in. Obviously Mexico is a place where we have a country manager, we have significant opportunity as soon as things become clearer from a regulatory perspective there.

The reason this is important is because Larry has extensive relationships with former generals in Mexico, the former Attorney General in Mexico…so as we expand and evolve into Mexico specifically, we know because of Larry’s relationships and his ability to leverage those relationships, that we will be able to be doing business there with the right people, people that are vetted, people that are experienced, people that are trusted. People that Larry and our former colleagues in Mexico worked with when they were assigned there, some that are still assigned there.

So these things are very important to me as Chief Compliance Officer in charge of the security for Khiron, and that’s just one example. Another example would be, we just hired Trevor Devine. Trevor’s a former DEA agent, just retired in the last month. He is a pilot; he is able to fly many different aircraft, both fixed-wing and rotary. He is also a Colonel in the United States Marine Corps, has extensive experience in moving logistics, moving personnel. He answers directly to General Maddis when he was active in places like Europe and central command and places like that.

As we speak, Trevor is deployed to Afghanistan, working over there with our military, with our marines, and with our contractors that are assigned there, working there. When he finishes up that assignment on August 5th, he will report to Khiron. He will report to me, and he is going to be working with Henry Tibaduiza, Khiron Security Director, to ensure that as we move our high-value product, which obviously is medical cannabis right now in Colombia, as we move our product from our grow site in Dorma (phon) which is approximately four, four and a half hours from Bogota to Bogota and other places, facilities, labs, in Colombia, and as we move our product to pharmacies in Colombia.

Trevor will be working closely with Henry and others in Colombia to ensure the safety of our transportation routes, ensuring that our logistics is properly tracked and traced, ensure that we are operating in a safe manner, and ensure that we are operating with the right people, obviously, in Colombia, where we’ll be moving product very soon.

We also brought on James Connelly. Jim Connelly is a criminal investigator with DEA that I’ve known for over 30 years; we were actually at college together. Jim has extensive experience with criminal investigations, special operations, and he was a country attache in the Bahamas. He also was a supervisor of a strike force. He also is a retired special agent in charge out of the Boston office, as was I. Worked very closely with Jim, and he’s going to help us ensure that, you know, we are vetting the right people, we are vetting people properly, that we are doing business with the right people throughout Khiron’s operations.

So we’re very, very excited about the addition of some of my former colleagues, because DEA, as an agency, operates in just about every country where the US has an embassy, and based on that, and based on our relationships with our counterparts in those countries, with our former colleagues in those countries, we have an extensive ability to draw back on those relationships to ensure that Khiron is operating in a safe manner, a compliant manner, and it just makes sense as the industry evolves to different countries, as Khiron evolves with it, as we go different places, we have people in those places that we can call. Some are friends, some are just former colleagues, but you know, we’re all on the same page, we all did the same thing for a long, long time.

So I’m very excited about that, and in regards to the National Cannabis Roundtable, Khiron joined the National Cannabis Roundtable, which is an entity headed up by our Chairpersons John Boehner, former Speaker of the House. The goal of the National Cannabis Roundtable is to bring common-sense Federal regulation to the cannabis industry in the US, as things start to move forward, and hopefully Federal legislation legalizing cannabis is imminent.

We would like to see prior to that, though, Safe Banking Act legislation passed so that cannabis companies in the US will no longer need to move money and product in, you know, Brinks trucks; they’ll be able to utilize banks and financial institutions to do banking like other legitimate businesses in the US and other countries are allowed to do.

James West: So be able to use the electronic banking system?

Matt Murphy: Yeah. I mean, we want to use whatever is legally available to other industries should be legal available to the cannabis industry, specifically right now in those states where cannabis is legal. And obviously, the hope and the goal is that cannabis is legal in every state; it’ll probably happen some time around the next election, I would think, because I think every candidate that has spoken about cannabis legislation is favourable towards it.

So what that looks like, you know, nobody knows right now. But hey, if we can at least get the banking law changed so that Federally, these companies could use banks, it would be a huge help, and it just makes sense, as you or anybody else that is involved in the industry knows, and we’ll see. I mean, there are a lot of initiatives that the NCR is working towards, and the group works closely with legislators in the US, and obviously with somebody of John Boehner’s stature, that is very helpful. Kevin Murphy from Acreage is a member and is, you know, working closely with John Boehner to assist in getting things done. So I’m very excited about that. It’s given me and Khiron, I should say, an inside look into how things work, and we are leaders in the industry at Khiron, and we expect to be in the US in a big way when Federal legislation changes the law. And you know, we already have a joint venture with Dixie, as you know, so we’re not shy about entering the US and there’s no reason to be, because it’s a huge market that we want to exploit when the time comes, and we want to be ready to move forward.

James West: You bet. All right, Matt, that’s a great update. Thank you very much for your participation as usual. We’ll leave it there for now, and come back to you soon. Thank you for joining me today.

Matt Murphy: All right. Thanks, James, look forward to talking to you again.

James West: You bet.

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.

Free Newsletter,
Priceless Content.

Be the first to hear from Midas Letter on all things Cannabis.